Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00072839 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of ALX-0600 in Subjects With Active Crohn's Disease
A Phase 2 study, sponsored by Shire.
- Completed
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
NCT00072839 is a Phase 2 study that has completed, run by Shire. The registered enrollment target is 100 participants.
The verdict
NCT00072839, a Phase 2 study, has completed, sponsored by Shire.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
Study Summary
The purpose of the study is to determine whether an investigational compound, ALX-0600, is safe and effective in treating Crohn's Disease.
Interventions
- DRUG placebo
- DRUG ALX-0600
- DRUG teduglutide 0.05
- DRUG teduglutide 0.2 mg
- DRUG Teduglutide 0.05 dose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2003-11-12 |
| Est. Completion | 2005-07-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00072839
The ClinicalTrials.gov registry entry for NCT00072839 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Shire, which has 245 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which placebo is the first listed.
NCT00072839 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00072839 about?
NCT00072839 is a clinical study titled "Safety and Efficacy of ALX-0600 in Subjects With Active Crohn's Disease". The purpose of the study is to determine whether an investigational compound, ALX-0600, is safe and effective in treating Crohn's Disease.
What is the current status of trial NCT00072839?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2003-11-12. Estimated completion is 2005-07-28.
What interventions are being tested in trial NCT00072839?
The interventions under investigation include: placebo (DRUG), ALX-0600 (DRUG), teduglutide 0.05 (DRUG), teduglutide 0.2 mg (DRUG), Teduglutide 0.05 dose (DRUG).
Who is sponsoring clinical trial NCT00072839?
This trial is sponsored by Shire, which has 245 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.